Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

With LAURUSLABS's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 1.320000
forwardPE 58.787064
debtToEquity 44.831000
earningsGrowth 8.757000
revenueGrowth 0.351000
grossMargins 0.558950
operatingMargins 0.171020
trailingEps 12.650000
forwardEps 23.370000

A current ratio of 1.32 for Laurus Labs Limited implies that the company has ample liquidity to meet its short-term debts. Laurus Labs Limited's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
LAURUSLABS's forward PE ratio is too high, which may hinder future price growth and increase the risk of a price correction. Investors should carefully evaluate this metric along with other key financial indicators to get a full picture of the stock's potential.
LAURUSLABS's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that LAURUSLABS will continue to grow its operations, driven by increasing profits and revenue.
LAURUSLABS's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that LAURUSLABS's financial performance will improve in the current financial year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

The price of LAURUSLABS has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


With analysts showing a sell bias toward LAURUSLABS, it's crucial for investors to approach decisions carefully. It's recommended to consult a broader base of market indicators rather than relying solely on the analysts' bias, as this will offer a more comprehensive view of the stock's prospects.